The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer

Radiat Oncol. 2010 Dec 15:5:119. doi: 10.1186/1748-717X-5-119.

Abstract

Background: We aim to investigate the possibility of using 18F-positron emission tomography/computer tomography (PET-CT) to predict the histopathologic response in locally advanced rectal cancer (LARC) treated with preoperative chemoradiation (CRT).

Methods: The study included 50 patients with LARC treated with preoperative CRT. All patients were evaluated by PET-CT before and after CRT, and results were compared to histopathologic response quantified by tumour regression grade (patients with TRG 1-2 being defined as responders and patients with grade 3-5 as non-responders). Furthermore, the predictive value of metabolic imaging for pathologic complete response (ypCR) was investigated.

Results: Responders and non-responders showed statistically significant differences according to Mandard's criteria for maximum standardized uptake value (SUVmax) before and after CRT with a specificity of 76,6% and a positive predictive value of 66,7%. Furthermore, SUVmax values after CRT were able to differentiate patients with ypCR with a sensitivity of 63% and a specificity of 74,4% (positive predictive value 41,2% and negative predictive value 87,9%); This rather low sensitivity and specificity determined that PET-CT was only able to distinguish 7 cases of ypCR from a total of 11 patients.

Conclusions: We conclude that 18-F PET-CT performed five to seven weeks after the end of CRT can visualise functional tumour response in LARC. In contrast, metabolic imaging with 18-F PET-CT is not able to predict patients with ypCR accurately.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma / diagnostic imaging*
  • Carcinoma / drug therapy
  • Carcinoma / metabolism
  • Carcinoma / radiotherapy
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Predictive Value of Tests
  • Prognosis
  • Rectal Neoplasms / diagnostic imaging*
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / metabolism
  • Rectal Neoplasms / radiotherapy
  • Sensitivity and Specificity

Substances

  • Fluorodeoxyglucose F18